null

VivoGenie Anti-Human IFNy (Emapalumab) Biosimilar (IVMB0492)

SKU:
IVMB0492
Antibody Type:
In Vivo Biosimilar
Endotoxin Level:
Low Endotoxin
Applications:
In Vivo
Disease Area:
Cancer
€679 - €1,589

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human IFNy (Emapalumab)
SKU:IVMB0492
Size:1 mg, 5 mg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:NI-0501
Target:IFN-γ
Isotype:Human IgG1 L2
Host Species:Human
Reactivity:Human
Applications:ELISA
Expression Host:HEK-293 Cells
FC Effector Activity:Active
Synonyms:Emapalumab,NI-0501,emapalumab-lzsg,IFNG ,1709815-23-5
Product Concentration:≥ 5.0 mg/ml
Purity:≥95% by SDS Page
Immunogen:Human IFNγ
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Antigen Distribution:IFNγ is produced by natural killer and natural killer T cells, T-helper 1 (Th1) CD4 + T cells, and CD8 + and cytotoxic T-lymphocytes.
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Specificity:Emapalumab activity is directed against human IFNγ.
Additional Applications Reported In Literature:ELISAWBIPFAFCNIF Microscopy
Recommended Isotype Controls:Human IgG1

IFNγ plays roles in Th1 differentiation, macrophage function, leukocyte migration to sites of infection, and increasing major histocompatibility complex expression to improve T-cellrecognition of infected or malignant cells 1. Hemophagocytic lymphohistiocytosis (HLH) is a rare but severe dysregulation of the immune system characterized by increased IFNγ production, macrophage and lymphocyte hyperactivity with tissue infiltration, hypersecretion of pro-inflammatory cytokines (CXCL9), hemophagocytosis, tissue damage, and multi-organ failure 2. IFNγ plays a central role in the pathophysiology of HLH, and blocking IFNγ leads to clinical improvement.

Emapalumab was developed by Novimmune and Swedish Orphan Biovitrum as an immunotherapeutic treatment for HLH 2. Emapalumab is a fully human IgG1 monoclonal antibody that targets and binds to IFNγ with high affinity. Emapalumab neutralizes IFNγ activity and inhibits interaction with its receptor by acting as a non-competitive inhibitor binding to free IFNγ and IFNγ-Receptor-1(IFNγR1)-bound IFNγ. Emapalumab inhibits receptor dimerization and transduction of interferon-γ signaling, impairing the interaction induced by IFNγ at the cell surface with IFNγR1 and IFNγ R2 and thereby neutralizing IFNγ biologic activity 2,3,4. Emapalumab prevents recruitment of IFNγR2 but has no effect on IFNγR1 endocytosis and internalization into lysosomes 2,4. In HLH patients, emapalumab reduces the plasma concentrations of the cytokine CXCL9.

Emapalumab is composed of anti-(human IFNγ) human monoclonal NI-0501 heavy chain, disulfide with human monoclonal NI-0501 light chain, dimer 2. Emapalumab is produced by recombinant DNA technology and is approximately 148 kDa 5.

Ligand/Receptor:IFNAR
State of Matter:Liquid
Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Product Preparation:Recombinant biosimilar antibodies are manufactured in an animal free facility using onlyin vitroprotein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
UniProt:Q14609
Research Area:Biosimilars

Related Products